Modality
ADC
MOA
WEE1i
Target
SHP2
Pathway
JAK/STAT
FabryPAH
Development Pipeline
Preclinical
~Nov 2015
→ ~Feb 2017
Phase 1
May 2017
→ Apr 2028
Phase 1Current
NCT03922298
1,401 pts·PAH
2017-05→2026-10·Active
NCT05381892
1,999 pts·Fabry
2025-09→2028-04·Recruiting
3,400 total pts2 indications
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2026-10-167mo awayPh2 Data· PAH
2028-04-072.0y awayPh2 Data· Fabry
Trial Timeline
Q2Q3Q42018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2
P1/2
Active
P1/2
Recruit…
Catalysts
Ph2 Data
2026-10-16 · 7mo away
PAH
Ph2 Data
2028-04-07 · 2.0y away
Fabry
RecruitingActive|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT03922298 | Phase 1/2 | PAH | Active | 1401 | PANSS |
| NCT05381892 | Phase 1/2 | Fabry | Recruiting | 1999 | NT-proBNP |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| JNJ-8637 | Johnson & Johnson | NDA/BLA | CD20 | |
| NVS-5126 | Novartis | Phase 3 | SHP2 | |
| MRK-1380 | Merck & Co | Preclinical | SHP2 | |
| MRK-853 | Merck & Co | Phase 1 | PRMT5 | |
| ABB-1817 | AbbVie | Phase 3 | SHP2 | |
| AZN-8281 | AstraZeneca | Phase 1 | SHP2 | |
| AZN-8478 | AstraZeneca | NDA/BLA | SHP2 | |
| Doxafotisoran | Daiichi Sankyo | Phase 1 | Cl18.2 | |
| MRN-7409 | Moderna | NDA/BLA | SHP2 | |
| GMA-1468 | Genmab | NDA/BLA | PI3Kα |